J. Wu-Wong

Potential for vitamin D receptor agonists in the treatment of cardiovascular disease

J. Wu-Wong, 2009, British journal of pharmacology.

Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption

Y. M. Yang, T. Ahmed, J. Wu-Wong, 2000, British Journal of Cancer.

Vitamin D Analogs Modulate the Expression of Plasminogen Activator Inhibitor-1, Thrombospondin-1 and Thrombomodulin in Human Aortic Smooth Muscle Cells

M. Nakane, J. Wu-Wong, Junli Ma, 2006, Journal of Vascular Research.

Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects.

J. Wu-Wong, M. Kawai, Barbara B. Chen, 2013, Bioorganic & medicinal chemistry letters.

A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.

S. Ng, J. Pietenpol, S. Rosenberg, 2001, Cancer research.

Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor.

K. Marsh, J. Wu-Wong, B. Dayton, 1999, European journal of pharmacology.

Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristics.

J. Wu-Wong, W. Chiou, J R Wu-Wong, 1997, The Journal of pharmacology and experimental therapeutics.

Statins do not directly activate vitamin D receptor

M. Nakane, J. Wu-Wong, T. Ju, 2007, Journal of thrombosis and haemostasis : JTH.